QQQ   427.17 (+0.31%)
AAPL   167.86 (-0.08%)
MSFT   411.11 (-0.18%)
META   508.80 (+2.96%)
GOOGL   156.22 (+0.48%)
AMZN   182.13 (+0.47%)
TSLA   150.47 (-3.20%)
NVDA   856.55 (+1.93%)
AMD   156.25 (+1.45%)
NIO   4.04 (+3.32%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   114.41 (-1.65%)
GE   156.70 (+0.66%)
CGC   7.68 (+18.34%)
DIS   113.75 (+0.72%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.67 (-0.93%)
XOM   118.96 (+0.28%)
QQQ   427.17 (+0.31%)
AAPL   167.86 (-0.08%)
MSFT   411.11 (-0.18%)
META   508.80 (+2.96%)
GOOGL   156.22 (+0.48%)
AMZN   182.13 (+0.47%)
TSLA   150.47 (-3.20%)
NVDA   856.55 (+1.93%)
AMD   156.25 (+1.45%)
NIO   4.04 (+3.32%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   114.41 (-1.65%)
GE   156.70 (+0.66%)
CGC   7.68 (+18.34%)
DIS   113.75 (+0.72%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.67 (-0.93%)
XOM   118.96 (+0.28%)
QQQ   427.17 (+0.31%)
AAPL   167.86 (-0.08%)
MSFT   411.11 (-0.18%)
META   508.80 (+2.96%)
GOOGL   156.22 (+0.48%)
AMZN   182.13 (+0.47%)
TSLA   150.47 (-3.20%)
NVDA   856.55 (+1.93%)
AMD   156.25 (+1.45%)
NIO   4.04 (+3.32%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   114.41 (-1.65%)
GE   156.70 (+0.66%)
CGC   7.68 (+18.34%)
DIS   113.75 (+0.72%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.67 (-0.93%)
XOM   118.96 (+0.28%)
QQQ   427.17 (+0.31%)
AAPL   167.86 (-0.08%)
MSFT   411.11 (-0.18%)
META   508.80 (+2.96%)
GOOGL   156.22 (+0.48%)
AMZN   182.13 (+0.47%)
TSLA   150.47 (-3.20%)
NVDA   856.55 (+1.93%)
AMD   156.25 (+1.45%)
NIO   4.04 (+3.32%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   114.41 (-1.65%)
GE   156.70 (+0.66%)
CGC   7.68 (+18.34%)
DIS   113.75 (+0.72%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.67 (-0.93%)
XOM   118.96 (+0.28%)
Free Trial

bluebird bio (BLUE) Stock Forecast & Price Target

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)
Free blue Stock Alerts
$0.95
-0.01 (-1.37%)
(As of 11:46 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

bluebird bio Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 12 Analyst Ratings

Analysts' Consensus Price Target

$5.87
517.83% Upside
High Forecast$13.00
Average Forecast$5.87
Low Forecast$1.02
TypeCurrent Forecast
4/19/23 to 4/18/24		1 Month Ago
3/20/23 to 3/19/24		3 Months Ago
1/19/23 to 1/19/24		1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$5.87$6.27$6.84$6.78
Predicted Upside517.83% Upside116.66% Upside102.31% Upside48.78% Upside
Get bluebird bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

BLUE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLUE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

bluebird bio Stock vs. The Competition

Typebluebird bioMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside509.36% Upside934.49% Upside12.27% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/27/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingSector Perform ➝ Sector Perform$6.00+370.59%
3/27/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00+150.00%
3/19/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$1.72 ➝ $1.68+16.67%
3/5/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetReduce ➝ Reduce$2.31 ➝ $1.02-33.33%
1/9/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Perform
12/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$12.00 ➝ $5.00+264.96%
12/12/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$10.00 ➝ $7.00+151.80%
12/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderweight ➝ Equal Weight$3.00 ➝ $7.00+45.53%
11/8/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$10.00 ➝ $13.00+267.23%
10/17/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		E. Schmidt
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageNeutral
6/1/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeEqual Weight ➝ Overweight$7.00 ➝ $8.00+138.81%
4/28/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$7.00+90.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:01 PM ET.

BLUE Price Target - Frequently Asked Questions

What is bluebird bio's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for bluebird bio stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for BLUE. The average twelve-month price prediction for bluebird bio is $5.87 with a high price target of $13.00 and a low price target of $1.02. Learn more on BLUE's analyst rating history.

Do Wall Street analysts like bluebird bio more than its competitors?

Analysts like bluebird bio less than other Medical companies. The consensus rating for bluebird bio is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how BLUE compares to other companies.

Does bluebird bio's stock price have much upside?

According to analysts, bluebird bio's stock has a predicted upside of 135.04% based on their 12-month stock forecasts.

What analysts cover bluebird bio?

bluebird bio has been rated by HSBC, Royal Bank of Canada, Wedbush, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:BLUE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Paradigm Press
Top 5 AI Stocks to Buy for 2024
Market Moving Trends